The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment

Inflammatory Bowel Diseases

Volumn 17, Issue 8, 2011, Pages 1651-1664

  Schicho, Rudolf ^a,b   Bashashati, Mohammad ^c   Bawa, Misha ^d   McHugh, Douglas ^f   Saur, Dieter ^e   Hu, Huang Ming ^c,g   Zimmer, Andreas ^h   Lutz, Beat ⁱ   MacKie, Ken ^f   Bradshaw, Heather B ^f   McCafferty, Donna Marie ^d   Sharkey, Keith A ^c   Storr, Martin ^a  

^a Division of Gastroenterology   (Canada)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e INDIANA UNIVERSITY   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^h UNIVERSITY OF BONN   (Germany)

ⁱ JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

atypical cannabinoids; colitis; inflammatory bowel disease

Indexed keywords

CANNABINOID; DEXTRAN SULFATE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; KERATINOCYTE DERIVED CHEMOKINE; O 1602; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL COLITIS; EXPERIMENTAL MOUSE; HISTOLOGY; KNOCKOUT MOUSE; MALE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTACTIC ASSAY; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; CANNABINOIDS; CHEMOTAXIS, LEUKOCYTE; COLITIS; COLON; CYCLOHEXANES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NEUTROPHIL INFILTRATION; NEUTROPHILS; PEROXIDASE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS; TRINITROBENZENESULFONIC ACID;

EID: 79960275004     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21538     Document Type: Article

References (56)

1. Ashton JC,. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs. 2007; 8: 373-384. (Pubitemid 46705390)
2. Jhaveri MD, Richardson D, Chapman V,. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol. 2007; 152: 624-632. (Pubitemid 350034979)
3. Pertwee RG,. Pharmacological actions of cannabinoids. Handb Exp Pharmacol. 2005; 1-51.
4. Jarai Z, Wagner JA, Varga K, et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A. 1999; 96: 14136-14141.
5. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007; 152: 1092-1101. (Pubitemid 350166046)
6. Brown AJ,. Novel cannabinoid receptors. Br J Pharmacol. 2007; 152: 567-575. (Pubitemid 350041541)
7. Kreitzer FR, Stella N,. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther. 2009; 122: 83-96.
8. Mackie K, Stella N,. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006; 8: E298-E306.
9. De Petrocellis L, Di Marzo V,. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009; 23: 1-15.
10. Johns DG, Behm DJ, Walker DJ, et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol. 2007; 152: 825-831. (Pubitemid 350034974)
11. Izzo AA, Camilleri M,. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res. 2009; 60: 117-125.
12. Massa F, Storr M, Lutz B,. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med. 2005; 83: 944-954. (Pubitemid 41745753)
13. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005; 129: 437-453. (Pubitemid 41096632)
14. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006; 291: G364-G371. (Pubitemid 44024696)
15. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004; 113: 1202-1209. (Pubitemid 38544105)
16. Storr MA, Keenan CM, Emmerdinger D, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med. 2008; 86: 925-936.
17. Storr MA, Keenan CM, Zhang H, et al. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009; 15: 1678-1685.
18. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001; 134: 563-570. (Pubitemid 32977900)
19. D'Argenio G, Valenti M, Scaglione G, et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 2006; 20: 568-570. (Pubitemid 46671252)
20. Sharma R, Tobin P, Clarke SJ,. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 2005; 6: 93-102. (Pubitemid 40197703)
21. Izzo AA, Borrelli F, Capasso R, et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009; 30: 515-527.
22. Pertwee RG,. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. Br J Pharmacol. 2008; 153: 199-215.
23. Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med. 2009; 87: 1111-1121.
24. Ross RA,. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci. 2009; 30: 156-163.
25. Waldeck-Weiermair M, Zoratti C, Osibow K, et al. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci. 2008; 121: 1704-1717. (Pubitemid 351911827)
26. McHugh D, Tanner C, Mechoulam R, et al. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol. 2008; 73: 441-450. (Pubitemid 351159214)
27. Kozol RA,. Neutrophil recruitment to the gastrointestinal tract. J Surg Res. 1992; 53: 310-315.
28. Lampinen M, Ronnblom A, Amin K, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut. 2005; 54: 1714-1720. (Pubitemid 41697669)
29. Zimmer A, Zimmer AM, Hohmann AG, et al. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999; 96: 5780-5785. (Pubitemid 29234695)
30. Wu CS, Zhu J, Wager-Miller J, et al. Requirement of cannabinoid CB1 receptor in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci. 2010 [Epub ahead of print].
31. Kimball ES, Wallace NH, Schneider CR, et al. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol Motil. 2004; 16: 811-818. (Pubitemid 40022788)
32. Wallace JL, Keenan CM,. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol. 1990; 258: G527-G534. (Pubitemid 20144071)
33. Krawisz JE, Sharon P, Stenson WF,. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984; 87: 1344-1350. (Pubitemid 15201434)
34. Khan AI, Heit B, Andonegui G, et al. Lipopolysaccharide: a p38 MAPK-dependent disrupter of neutrophil chemotaxis. Microcirculation. 2005; 12: 421-432. (Pubitemid 41122466)
35. Saur D, Paehge H, Schusdziarra V, et al. Distinct expression of splice variants of neuronal nitric oxide synthase in the human gastrointestinal tract. Gastroenterology. 2000; 118: 849-858. (Pubitemid 30243748)
36. Brusberg M, Arvidsson S, Kang D, et al. CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents. J Neurosci. 2009; 29: 1554-1564.
37. Raab Y, Gerdin B, Ahlstedt S, et al. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis. Gut. 1993; 34: 1203-1206. (Pubitemid 23274540)
38. Engel MA, Neurath MF,. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010 [Epub ahead of print].
39. Sandborn WJ,. The future of inflammatory bowel disease care. Rev Gastroenterol Disord. 2009; 9: E69-E77.
40. Sawzdargo M, Nguyen T, Lee DK, et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999; 64: 193-198. (Pubitemid 29052470)
41. Howlett AC, Qualy JM, Khachatrian LL,. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986; 29: 307-313. (Pubitemid 16137598)
42. Lauckner JE, Jensen JB, Chen HY, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008; 105: 2699-2704. (Pubitemid 351520576)
43. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 2008; 139: 225-236.
44. Carlson M, Raab Y, Seveus L, et al. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut. 2002; 50: 501-506. (Pubitemid 34638869)
45. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003; 52: 847-853. (Pubitemid 36613492)
46. Izzo RS, Witkon K, Chen AI, et al. Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol. 1992; 87: 1447-1452.
47. Lampinen M, Sangfelt P, Taha Y, et al. Accumulation, activation, and survival of neutrophils in ulcerative colitis: regulation by locally produced factors in the colon and impact of steroid treatment. Int J Colorectal Dis. 2008; 23: 939-946.
48. Hans W, Scholmerich J, Gross V, et al. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw. 2000; 11: 67-74. (Pubitemid 30145404)
49. Qualls JE, Kaplan AM, van RN, et al. Suppression of experimental colitis by intestinal mononuclear phagocytes. J Leukoc Biol. 2006; 80: 802-815. (Pubitemid 44835899)
50. Bento AF, Leite DF, Claudino RF, et al. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol. 2008; 84: 1213-1221.
51. Farooq SM, Stillie R, Svensson M, et al. Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther. 2009; 329: 123-129.
52. Morohoshi Y, Matsuoka K, Chinen H, et al. Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol. 2006; 41: 318-324. (Pubitemid 43834374)
53. McHugh D, Hu SS, Rimmerman N, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010; 11: 44.
54. Kojouharoff G, Hans W, Obermeier F, et al. Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol. 1997; 107: 353-358. (Pubitemid 27049264)
55. Naito Y, Takagi T, Handa O, et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol. 2003; 18: 560-569. (Pubitemid 36645291)
56. Xu Y, Hunt NH, Bao S,. The correlation between proinflammatory cytokines, MAdCAM-1 and cellular infiltration in the inflamed colon from TNF-alpha gene knockout mice. Immunol Cell Biol. 2007; 85: 633-639. (Pubitemid 350224210)